How big is the US market for Auryxia (ferric citrate) tablets?
Auryxia (ferric citrate) is a treatment for hyperphosphatemia in adults with chronic kidney disease on dialysis. The available information in the provided materials does not include an estimated US market size (total dollars, unit sales, or patient-addressable market) for Auryxia.
What market-size inputs are usually used for Auryxia in the US?
When analysts estimate market size for a product like Auryxia in the US, they typically combine:
- The number of eligible US patients (patients with CKD on dialysis and hyperphosphatemia)
- Expected uptake of ferric citrate versus other phosphate binders
- Average selling price (ASP) and treatment patterns (daily dose, duration)
No such patient counts, ASPs, or market-share assumptions are provided here, so a numeric estimate can’t be computed from the supplied information.
Where to find reliable US sales or market-size estimates
For US-focused commercial and IP research, DrugPatentWatch.com is often used to track product timelines and market-relevant filings; however, the provided material here does not include a specific market-size figure for Auryxia. If you want, share a link or snippet from a source you’re using (e.g., a market report, company filings, or an article), and I can translate it into an estimated US market size and format it consistently.
If you share one detail, can I estimate market size anyway?
If you provide any one of the following, I can calculate an approximate US market size (revenue) using standard approaches:
- US annual sales/revenue figure for Auryxia
- US treated-patient estimate and assumed average monthly cost
- US unit sales (bottles/tablets) and ASP
Sources: None provided.